Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Guardant Health Inc (NASDAQ: GH) was $50.03 for the day, up 0.26% from the previous closing price of $49.9. In other words, the price has increased by $0.26 from its previous closing price. On the day, 2.0 million shares were traded. GH stock price reached its highest trading level at $50.32 during the session, while it also had its lowest trading level at $48.07.
Ratios:
Our analysis of GH’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.76 and its Current Ratio is at 4.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $55.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $60.
Guggenheim Upgraded its Neutral to Buy on June 28, 2024, while the target price for the stock was maintained at $36.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 18 ’25 when Tariq Musa sold 3,213 shares for $49.47 per share. The transaction valued at 158,947 led to the insider holds 7,190 shares of the business.
POTTER MYRTLE S sold 26 shares of GH for $1,286 on Jun 18 ’25. The Director now owns 18,154 shares after completing the transaction at $49.47 per share. On Jun 17 ’25, another insider, CLARK IAN T, who serves as the Director of the company, sold 6,672 shares for $48.38 each. As a result, the insider received 322,819 and left with 9,851 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 6198116352 and an Enterprise Value of 6805929984. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.01. Its current Enterprise Value per Revenue stands at 8.793 whereas that against EBITDA is -16.492.
Stock Price History:
The Beta on a monthly basis for GH is 1.41, which has changed by 0.7323407 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $52.92, while it has fallen to a 52-week low of $20.14. The 50-Day Moving Average of the stock is 11.57%, while the 200-Day Moving Average is calculated to be 34.40%.
Shares Statistics:
GH traded an average of 2.21M shares per day over the past three months and 2030270 shares per day over the past ten days. A total of 123.65M shares are outstanding, with a floating share count of 117.69M. Insiders hold about 5.00% of the company’s shares, while institutions hold 96.70% stake in the company. Shares short for GH as of 1749772800 were 9998417 with a Short Ratio of 4.52, compared to 1747267200 on 9122472. Therefore, it implies a Short% of Shares Outstanding of 9998417 and a Short% of Float of 8.469999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Guardant Health Inc (GH) reflects the combined expertise of 13.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.31 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$1.11 and -$2.36 for the fiscal current year, implying an average EPS of -$1.99. EPS for the following year is -$1.68, with 14.0 analysts recommending between -$1.34 and -$2.08.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 19 analysts. It ranges from a high estimate of $219.1M to a low estimate of $202.02M. As of the current estimate, Guardant Health Inc’s year-ago sales were $177.24MFor the next quarter, 19 analysts are estimating revenue of $226.33M. There is a high estimate of $229.5M for the next quarter, whereas the lowest estimate is $220.24M.
A total of 22 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $892.1M, while the lowest revenue estimate was $855M, resulting in an average revenue estimate of $883.94M. In the same quarter a year ago, actual revenue was $739.02MBased on 22 analysts’ estimates, the company’s revenue will be $1.07B in the next fiscal year. The high estimate is $1.14B and the low estimate is $1B.
